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5 Na V 1.7 channels (Cummins et al., 1998) . Within rodent DRGs, Na V 1.7 is preferentially expressed in small diameter nociceptive neurons (Djouhri et al., 2003) and is upregulated in response to inflammation (Black et al., 2004; Yeomans et al., 2005) . A role of Na V 1.7 in mediating inflammatory pain signaling in rodents is further supported by the finding that knockdown of Na V 1.7 expression, either through herpes vector-mediated application of antisense oligonucleotides or by nociceptor-specific genetic ablation, reduces the development of inflammatory hyperalgesia (Nassar et al., 2004; Yeomans et al., 2005) .
Further analysis of the function of Na V 1.7 in pain signaling would benefit from the discovery of a Na V 1.7-selective sodium channel blocker. Historically, truly subtypeselective sodium channel blockers have been rare, and, despite significant efforts by the pharmaceutical industry, only few subtype-selective small molecule blockers have been published to date (Jarvis et al., 2007; Rosker et al., 2007; Williams et al., 2007) .
Peptides found in the venoms of snakes and spiders have been a rich source of ion channel modulators and are often highly selective. Indeed, ProTx-II from the tarantula Thrixopelma prurient has been reported as a blocker of Na V 1.7 channels (Middleton et al., 2002; Smith et al., 2007) . In this manuscript, we show that ProTx-II is at least 100-fold selective for Na V 1.7 over other sodium channel subtypes and provides a versatile experimental tool for studying the role of Na V 1.7. MOL #47670 8 constructs were transiently transfected into TsA-201 cells, together with an expression plasmid for green fluorescent protein, using FuGENE™6 from Roche (Basel, Switzerland).
Acute and Inflammatory Pain Tests. For intrathecal administration of drugs, animals
were anesthetized with isoflurane and a catheter was inserted into the subarachnoid space at L5-L6 of the spinal column. The catheter was flushed and filled with artificial cerebrospinal fluid (aCSF) and plugged. The exposed incision was closed with sutures and wound clips, and animals were allowed to recover for four days. At the end of an experiment, animals were injected with 10 µL of 2% lidocaine, followed by a 15 µL aCSF flush, and hind limb paralysis was used to verify proper implantation of the intrathecal catheter.
Local inflammation was induced by subcutaneous injection of 50 µL Complete Freund's
Adjuvant (CFA) into the plantar surface of the left hind paw. Withdrawal thresholds to a noxious mechanical stimulus were measured in the inflamed (ipsilateral) and uninjured (contralateral) hind paw using a Ugo Basile apparatus (Stoelting Co. Wood Dale, Il). Paw pressure was applied to the plantar surface of the paw by a dome-shaped plastic tip placed between the third and fourth metatarsus, and increased linearly until the animal vocalized, withdrew the paw or struggled. To avoid tissue damage, a cut-off pressure was set at 390 g on the ipsilateral paw and 750 g on the contralateral paw. Mechanical threshold was defined as the force in grams at the first pain behavior, and data are presented as mean and standard error of the mean for the inflamed and uninjured paw.
Hyperalgesia of the inflamed paw was determined by comparing mechanical thresholds in the ipsilateral and contralateral paw using an unpaired t test. The effect of ProTx-II on This article has not been copyedited and formatted. The final version may differ from this version. hyperalgesia was analyzed at each time point by using a one-way analysis of variance (ANOVA). Planned comparisons of means (each group compared to saline) were performed using a Dunnett's post hoc test.
Isolated Nerve Preparation. The skin-nerve in vitro preparation was used to record Aβ-and C-fiber sensory nerve compound action potentials (SNAP). Female Sprague-Dawley rats, weighing 300 to 400 g, were killed by cervical dislocation. The skin of the hind limb and the attached saphenous nerve were removed as previously described (Reeh, 1986) .
The preparation was mounted corium-side up in an organ bath and superfused with oxygenated synthetic interstitial fluid (SIF) consisting of (in mmol): 108 NaCl, 3.5 KCl, 3.5 MgSO 4 , 26 NaHCO 3 , 1.5 CaCl 2 , 9.6 sodium gluconate, 5.55 glucose, 7.6 sucrose and 10 HEPES, pH 7.40. The temperature of the bath was maintained at 32 °C. The proximal end of the nerve was isolated from SIF by liquid paraffin, desheathed and teased into filaments suitable for recording from single nerve fibers. Recordings were obtained with a pair of gold wire electrodes, a custom-made low noise differential amplifier in common rejection mode, a low pass filter of 1 KHz, and a high pass filter of 1 Hz. A self-sealing stainless steel ring (inner diameter 6 mm, outer diameter 8 mm) was placed on top of a section of the saphenous nerve and filled with liquid paraffin at 32°C. In some experiments, the nerve section covered by the stainless steel ring was desheathed prior to the experiment. The whole nerve was stimulated using Ag/AgCl electrodes with a noninsulated tip diameter of 2 mm (EPO5, World Precision Instruments, Hertfordshire, UK) at a frequency of 1 Hz (Aβ-volley) or 0.25 Hz (C-volley), a stimulus width of 0.2 ms (Aβ-volley) or 2 ms (C-volley), and an intensity of 5-20 V. The amplitude of the SNAP was measured peak-to-peak and expressed as a percentage of control for different This article has not been copyedited and formatted. The final version may differ from this version. 
Results
ProTx-II is a 30 amino acid peptide from the tarantula Thrixopelma prurien and had previously been identified as a sodium channel modulator (Middleton et al., 2002; Smith et al., 2007) . ProTx-II belongs to the cystine-knot family of inhibitory peptides and inhibits sodium currents by an effect on conductance combined with a shift of the activation voltage to more positive potentials.
Selectivity of ProTx-II for Na V 1.7. Previous results had indicated that ProTx-II interacted more potently with Na V 1.7 than with Na V 1.5 channels (Smith et al., 2007) . To characterize the selectivity of ProTx-II in more detail, we examined its effects on seven out of the nine hNa V 1 subunits identified to date. Since ProTx-II acts in part by shifting the voltage-dependence of channel activation to more positive potentials, inhibitory effects are dependent on test pulse potential. To standardize the protocol across Na V 1 subtypes with different activation voltages, the test pulse potential was set to the average V 0.5 of channel activation for each Na V 1 subtype in the stable cell line used for the ProTx-II experiments (Na V 1.2: -13 mV; Na V 1.3: -5 mV; Na V 1.4: -20 mV; Na V 1.5: -28 mV; Na V 1.6: -20 mV; Na V 1.7: -8 mV; Na V 1.8: +5 mV). Short (6 ms) test pulses were applied at 0.5 Hz from a holding potential at which steady-state inactivation was minimal, ranging from -90 mV for Na V 1.8 to -110 mV for Na V 1.5. Figure 1A shows block of hNa V 1.6 (open squares) and hNa V 1.7 (filled squares) by 10 nM ProTx-II under these conditions; resulting in 26% and 99% block, respectively. Data for all seven Na V 1 subtypes tested are summarized in Figure 1B and consist of at least three data points for IC 50 s: Na V 1.2: 41 nM; Na V 1.3: 102 nM; Na V 1.4: 39 nM; Na V 1.5: 79 nM; Na V 1.6: 26 nM; Na V 1.7: 0.3 nM; Na V 1.8: 146 nM. A more accurate determination of the IC 50 for block of Na V 1.7 by ProTx-II, achieved by testing lower concentrations of the peptide, would be desirable but was precluded by the exceedingly long application times required to reach steady-state inhibition levels. Nevertheless, the data show that ProTx-II is at least 100-fold selective for block of Na V 1.7 over the six other Na V 1 subtypes tested.
Site of action of ProTx-II on Na V 1.7. Assuming that the binding site for ProTx-II resides within the transmembrane helices or in the extracellular domains of sodium channels, we examined the sequences of all hNa V 1 subtypes for amino acid residues in these regions that are conserved among hNa V 1 subtypes other than hNa V 1.7 and subject to a nonconservative substitution in hNa V 1.7. One such amino acid is found at position 839 (based on the Na V 1.2 sequence) in the S3b helix of domain II, where a phenylalanine in hNa V 1.7 (F813) replaces a glycine residue in the other hNa V 1 subtypes, except for a serine in hNa V 1.6 ( Figure 2A ). Mutating phenylalanine 813 in hNa V 1.7 to glycine (F813G), resulted in channels with similar voltage-dependence of activation (V 0.5 of -12 ± 1 mV, n = 7, versus -8 ± 1 mV, n = 7) and inactivation (V 0.5 of -62 ± 2 mV, n = 7, versus -68 ± 1 mV, n = 107) compared to wild-type hNa V 1.7 channels. Channels with a serine in position 813 (F813S) displayed a similar voltage-dependence of activation (V 0.5 of -9 ± 2 mV, n = 4) compared to wild-type hNa V 1.7 channels, but inactivated at more depolarized potentials (V 0.5 of -34 ± 1 mV, n = 3, p < 0.01). Remarkably, both mutant constructs, hNa V 1.7 F813G and F813S, were approximately 100-fold less sensitive to block by ProTx-II than wild-type channels ( Figure 2B ,C). Indeed the IC 50 for block of hNa V 1.7 F813G and hNa V 1.7 F813S channels by ProTx-II was 27 nM and 31 nM, This article has not been copyedited and formatted. The final version may differ from this version. G839F channels, expressed transiently in TsA-201 cells, activated at slightly more depolarized voltages than the stably expressed wild-type hNa V 1.2 channels (V 0.5 of -7.8 ± 1.5 mV, n = 8, versus -12.5 ± 0.9 mV, n = 8, p = 0.017). This difference is consistent with an effect of the β1 subunit, co-expressed in the stable cell line but absent in the transiently expressed mutant channels (Isom et al., 1995) . Block of Na V 1.2 G839F by ProTx-II was not significantly different from block of Na V 1.2 wild-type channels (p = 0.1) with IC 50 s of 25 nM and 41 nM for Na V 1.2 G839F and Na V 1.2 wild-type channels, respectively.
Efficacy in rat models of acute nociception and inflammation-induced hyperalgesia.
ProTx-II was examined for effects on acute nociception and inflammation-induced hyperalgesia by testing the response to noxious mechanical stimuli in the ipsilateral and contralateral paw of rats injected with Complete Freund's Adjuvant (CFA) to produce a local inflammation. Twenty-four hours following the CFA injection, withdrawal thresholds to a noxious mechanical stimulus (paw pressure) were assessed in both hind paws and compared to baseline measurements taken 24 hours prior to CFA injection.
Consistent with data reported in the literature, all animals developed mechanical hyperalgesia in the inflamed hindpaw, resulting in withdrawal thresholds of 131 ± 6 g in the inflamed ipsilateral paw compared to 406 ± 9 g in the contralateral paw (p < 0.001 unpaired t test, n = 40). Intravenous administration of saline had no effect on withdrawal thresholds in the ipsilateral or contralateral paw (p = 0.12 and p = 0.07, respectively, This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. Effects of ProTx-II on A-and C-fiber conduction. To examine the effect of ProTx-II on action potential firing in intact and desheathed sensory nerves, rat saphenous nerves were isolated and placed into a perfused organ bath ( Figure 4A ). Using standard recording techniques, Aβ-and C-fiber compound action potentials were recorded. In a first set of experiments (n = 3), 20 µM ProTxII was applied to the intact (non-desheathed) saphenous nerve and the amplitude of the C-fiber sensory nerve action potential (SNAP) was monitored for 10 minutes. There was no significant reduction in the amplitude of the C-fiber SNAP (100 ± 1% and 105 ± 9% of control after 5 min and 10 min, respectively).
When the same concentration of ProTx-II was applied to the desheathed nerve, the C- Figure 6B and 6C, respectively. Incubation of stably expressed hNa V 1.7/β1 channels with 75 pM This article has not been copyedited and formatted. The final version may differ from this version. and Catterall, 2000) . Tetrodotoxin (100 nM, site 1), veratridine (100 µM, site 2), the alpha-scorpion toxins LqhαIT and Ltx-004 and the sea anemone toxin Anthopleurin B (100 nM, site 3), the beta-scorpion toxins CssII and CssIV (100 nM, site 4), brevetoxin (100 nM, site 5), deltamethrin (10 µM, site 7), tetracaine and mexiletine (100 µM, site 9) all had no effect on 
Discussion
We have shown that ProTx-II inhibits Na V 1.7 with an IC 50 of 0.3 nM and is at least 100-fold selective for Na V 1.7 over other sodium channel subtypes. This subtype selectivity was abolished by a point mutation in the S3b segment of domain II. In desheathed sensory nerves, ProTx-II completely inhibited evoked C-fiber compound action potential at concentrations that had little effect on Aβ-fiber conduction. Radiolabeled ProTx-II was shown to bind with high affinity to cells expressing hNa V 1.7 channels and may serve as a tool to find Na V 1.7 selective small molecule blockers which may be considered for clinical development.
Recently, compelling human genetic evidence has identified Na V 1.7 as an essential contributor to pain signaling (Dib-Hajj et al., 2007) . Human loss-of-function mutations cause channelopathy-associated indifference to pain (CIP); whereas gain-of-function mutations underlie two inherited painful neuropathies: erythromelalgia (Han et al., 2006; Yang et al., 2004) and paroxysmal extreme pain disorder (Fertleman et al., 2006) . The absence, in patients with CIP, of cognitive, sensory or motor deficits, not related to the inability to sense pain, make Na V 1.7 an attractive target for the development of novel analgesics. However, pharmacological intervention with Na V 1.7 blockers may not reproduce the human loss-of-function phenotype, if either the lack of pain or the absence of a sympathetic defect in CIP patients is attributable to developmental changes.
Therefore, proof-of-concept experiments in experimental pain models require the development of Na V 1.7-selective channel modulators.
ProTx-II, a 30 amino acid peptide found in tarantula venom, is a potent inhibitor of Na V 1.7 channels, and we show here that ProTx-II is at least 100-fold selective for Na V 1.7
This article has not been copyedited and formatted. The final version may differ from this version. over other Na V 1 subtypes. ProTx-II inhibits sodium channels by decreasing channel conductance and shifting activation to more positive potentials. Based on the biophysical properties of Na V 1.7, this mechanism of action may be ideally suited to confer analgesic properties. Relative to other Na V 1 subtypes, Na V 1.7 transitions slowly from the resting to the inactivated state and conducts significant current in response to ramp depolarizations;
properties that suggest that Na V 1.7 may modulate firing thresholds by amplifying generator potentials (Cummins et al., 1998) . If Na V 1.7 indeed acts predominantly as a threshold channel in nociceptors, shifting the voltage dependence of activation to more positive potentials may decrease neuronal excitability and pain sensitivity while preserving the ability to sense acute painful stimuli. Intravenous or intrathecal administration of ProTx-II at tolerated doses in rats was not associated with significant inhibition of acute or inflammatory pain responses. A likely explanation for this lack of efficacy is an inability of ProTx-II to cross the blood-nerve barrier. This hypothesis was supported by the observation that ProTx-II inhibited C-fiber action potential propagation in desheathed but not in intact nerve preparations. While its biophysical properties may limit the usefulness of ProTx-II for in vivo proof-of-concept experiments, the peptide provides an important tool that can be used to find novel selective inhibitors of Na V 1.7.
Furthermore, ProTx-II can be used to investigate the contribution of different sodium channel subtypes to excitability control of sensory neurons. It has been suggested that action potential generation in small diameter (C-fiber) nociceptors is initiated by TTXsensitive conductances (presumably mediated by Na V 1.7); whereas the majority of the inward current during the action potential upstroke is mediated by Na V 1.8 (Blair and Bean, 2002; Renganathan et al., 2001) . The results presented here show that Na V 1.7 is This article has not been copyedited and formatted. The final version may differ from this version. required for action potential propagation in rat nociceptors. A potential explanation for this finding is that amplification of subthreshold depolarizations by activation of Na V 1.7 channels may be required to reach the more depolarized threshold of activation of Na V 1.8 channels. This hypothesis is supported by the discovery that a gain-of-function mutation in Na V 1.7 depolarizes the resting membrane potential and causes hyperexcitability in sensory neurons expressing Na V 1.8 channels, but renders sympathetic ganglion neurons, devoid of Na V 1.8 expression, hypoexcitable . At high concentrations, ProTx-II resulted in a block of action potential propagation in many Aβ-fibers. One possibility is that most Aβ−fibers express Na V 1.7 albeit at lower levels. However, if this were the case, the stimulus-response function should not be right-shifted relative to the Cfiber stimulus-response. A more likely explanation therefore is that, at higher concentrations, blockade of Na V 1.6 produces failure of action potential propagation in Aβ−fibers.
ProTx-II and a related tarantula venom peptide, ProTx-I, inhibit sodium channels by a mechanism similar to that of the potassium channel gating modifiers hanatoxin and SGTx1 (Lee et al., 2004; Swartz and MacKinnon, 1997) . Indeed, ProTx-I shares significant sequence homology with hanatoxin. ProTx-II also contains six disulfide bonded cysteine residues and conforms to the inhibitory cystine knot motif seen in other gating modifiers, but otherwise shares no sequence homology with ProTx-I or hanatoxin.
Extensive mutagenesis studies have shown that residues in S3b and in the N-terminal portion of S4 of K V 2.1 play crucial roles in channel modulation by hanatoxin (Li-Smerin and Swartz, 2000) . Similar to hanatoxin (Takahashi et al., 2000) , the structure of ProTx-II is amphipathic, with mostly hydrophobic residues on one face of the toxin. AlanineThis article has not been copyedited and formatted. The final version may differ from this version. scanning mutagenesis has shown that toxin residues involved in channel interactions are concentrated on the face of the toxin containing mostly hydrophobic and a few positively charged residues (Smith et al., 2007) . Membrane partitioning is thought to be involved in the mechanism of potassium channel inhibition by gating modifiers such as hanatoxin (Milescu et al., 2007) . In sodium channels, S3, S4 and the short linker segment are highly conserved between subtypes. Na V 1.7 is unique in that residue 813 in the C-terminal portion of domain II S3 is a phenylalanine, whereas all other Na V 1 subtypes carry a glycine residue in this position except for Na V 1.6 which has a serine residue. F813
appears to be crucial for conferring high sensitivity to ProTx-II, since mutation of F813
to glycine or serine in Na V 1.7 resulted in mutant channels with ProTx-II sensitivity reduced by ~100-fold and in the range of sensitivities of other Na V 1 subtypes. Mutating the equivalent glycine residue in Na V 1.2 (G839) to phenylalanine did not significantly increase sensitivity to ProTx-II, suggesting that phenylalanine in this position is necessary but not sufficient to confer high affinity for ProTx-II. Interestingly, F813 in Na V 1.7 is located six amino acids from a glycine residue (G845 in Na V 1.2) that is essential for high-affinity interaction of the β-scorpion toxin Css IV with Na V 1.2 (Cestele et al., 1998) . Similar to ProTx-II, β-scorpion toxins act by reducing channel conductance and interacting with the voltage sensor; however, in contrast to ProTx-II, β-scorpion 102 nM; Na V 1.4: 39 nM; Na V 1.5: 79 nM; Na V 1.6: 26 nM; Na V 1.7: 0.3 nM; Na V 1.8: 146 nM. 
